Jump to content

Intas Biopharmaceuticals: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Reverted edits by வெடால் (talk) (HG) (3.4.10)
Reverted edits as all the edits done by me has sources
Line 1: Line 1:
{{Use dmy dates|date=June 2018}}
{{Use dmy dates|date=June 2018}}
{{Use Indian English|date=June 2018}}
{{Use Indian English|date=June 2018}}

{{Infobox company |
⚫
'''Intas Biopharmaceuticals Ltd''' is an [[India|Indian]] [[Multinational corporation|multinational]] [[Corporation|company]] headquartered in [[Ahmedabad, India|Ahmedabad,]] [[Gujarat]]. It was founded by Dr. Urmish Chudgar and is now headed by Hasmukh Chudgar. The Biologics unit (BU) of the company is located in [[Ahmedabad]] and it is one of the leading [[biosimilar]] product manufacturers in [[Asia]]. The unit (BU) has its own biopharmaceutical operations with a R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.<ref>{{cite news |title=Intas mfg unit gets EU-GMP certification| date= 13 June 2007 | publisher= The Economic Times|url=http://economictimes.indiatimes.com/News/News_By_Industry/Healthcare__Biotech/Biotech/Intas_mfg_unit_gets_EU-GMP_certification/rssarticleshow/2118921.cms}}</ref>{{Infobox company
| name = Intas Pharmaceuticals - Biologics Business Unit
| name = Intas Biopharmaceuticals
| logo = Intasbio logo.png
| logo = Intasbio logo.png
| logo_caption = Logo of Intas Biopharmacueticals
| type = Limited
| image = Intas Biopharmacueticals.jpg
⚫
| foundation = 1984
| image_caption = Headquarters of Intas Biopharmaceuticals
⚫
| location = [[Ahmedabad, India]]
| industry = [[Biotechnology]]
| type = [[Private company|Private]]
⚫
| foundation = {{Start date and age|1984}}
⚫
| products = Neukine (GCSF), Erykine (EPO), Intalfa (IFN), Pegasta (Peg GCSF), Terifrac (Teriparatide), Mabtas (Rituximab), Folisurge (FSH)
| founder = Dr. Urmish Chudgar
⚫
| num_employees = 8000
⚫
| location = [[Ahmedabad]], [[Gujarat]]
| hq_location_country = [[India]]
| industry = [[Biopharmaceuticals]]
| area_served = Worldwide
⚫
| products = Neukine (GCSF) <br> Erykine (EPO) <br> Intalfa (IFN) <br> Pegasta (Peg GCSF) <br> Terifrac (Teriparatide) <br> Mabtas (Rituximab) <br> Folisurge (FSH)
| revenue = {{up}} [[₹]] 12,600 [[crore]] <br> ([[US$]] 1.8 Billion)
| revenue_year = 2019
| net_income = {{up}} [[₹]] 1,248 [[crore]] <br> ([[US$]] 204 [[Million]])
| net_income_year = 2019
⚫
| num_employees = 8000+
| num_employees_year = 2021
| homepage = {{URL|https://www.intaspharma.com/}}
| homepage = {{URL|https://www.intaspharma.com/}}
}}
}}


⚫
== History ==
The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as '''Intas Biopharmaceuticals Ltd.''' Intas Pharmaceuticals limited is an Indian [[Corporation|company]] headquartered in [[Ahmedabad, India]]. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading [[biosimilar]] product manufacturers in Asia.
⚫
Intas Biopharmaceuticals Limited was set up in 1980 by Dr. Urmish Chudgar, a [[Hematology|hematologist]], as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Hasmukh Chudgar.


== Present ==
⚫
The Biologics BU of Intas Pharmaceuticals has biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.<ref>{{cite news |title=Intas mfg unit gets EU-GMP certification| date= 13 June 2007 | publisher= The Economic Times|url=http://economictimes.indiatimes.com/News/News_By_Industry/Healthcare__Biotech/Biotech/Intas_mfg_unit_gets_EU-GMP_certification/rssarticleshow/2118921.cms}}</ref>
⚫
The company faced an EU-GMP ([[Good Manufacturing Practice]]) audit in December 2006, to seek approval for a clinical trial of its [[biosimilar]] [[Filgrastim]] in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.<ref>{{Cite news|title=Intas mfg unit gets EU-GMP certification|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/intas-mfg-unit-gets-eu-gmp-certification/articleshow/2118921.cms?from=mdr|access-date=2021-07-04}}</ref>


⚫
Apart from EU-GMP certification, the company has approvals from MCC [[South Africa]], [[Gulf Cooperation Council]] (GCC), [[Syria]], [[Yemen]], [[Belarus]] and several other national health authorities for its manufacturing facility and products.<ref>{{Cite web|title=About Us – Intas Pharmaceuticals Ltd.|url=https://www.intaspharma.com/about-us/|access-date=2021-07-04|language=en-US}}</ref><ref>{{Cite web|date=2015-01-23|title=Intas's Growth Driver : Biopharmaceuticals|url=https://nckpharma.com/intas-growth-driver-biopharmaceuticals/|access-date=2021-07-04|website=NCK Pharma|language=en-US}}</ref>
⚫
== History ==
⚫
Intas Biopharmaceuticals Limited was set up in 1980 by [[Dr Urmish Chudgar]], a leading hematooncologist, as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Mr. [[Hasmukh Chudgar]].


== Products ==
[[File:Intas Biopharmacueticals.jpg|thumb|300px|right|Corporate headquarters and production site of Intas Biopharmaceuticals Ltd.]]
In 2015, the company launched Accofil, a treatment for immune system disorders.<ref>{{cite web|author=|date=23 February 2015|title=Intas Pharma launches its first biosimilar product Accofil in Europe|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-pharma-launches-its-first-biosimilar-product-accofil-in-europe/articleshow/46342034.cms|access-date=25 April 2019|publisher=|via=The Economic Times}}</ref><ref>{{cite web|last=Reporter|first=B. S.|date=23 February 2015|title=Ahmedabad-based Intas Pharma launches biosimilar in EU|url=https://www.business-standard.com/article/companies/ahmedabad-based-intas-pharma-launches-biosimilar-in-eu-115022300721_1.html|access-date=25 April 2019|publisher=|via=Business Standard}}</ref>
⚫
The company faced an EU-GMP ([[Good Manufacturing Practice]]) audit in December 2006, to seek approval for a clinical trial of its [[biosimilar]] [[Filgrastim]] in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.


{{Gallery|Rituximab ( MabTas ).jpg|MabTas is Rituximab biosimilar of Intas|Accofil.JPG|Intas manufactured Filgrastim (Accofil) registered in EU|title=Products of Intas Biopharmaceuticals and timeline|width=160|height=170|align=center|Intas product development timeline.png|Intas Biosimilar development timeline}}
⚫
Apart from EU-GMP certification, the company has approvals from MCC [[South Africa]], [[Gulf Cooperation Council]] (GCC), [[Syria]], [[Yemen]], [[Belarus]] and several other national health authorities for its manufacturing facility and products.


== Financials ==
⚫
In 2015, the company launched Accofil, a treatment for immune system disorders.<ref>{{cite web|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-pharma-launches-its-first-biosimilar-product-accofil-in-europe/articleshow/46342034.cms|title=Intas Pharma launches its first biosimilar product Accofil in Europe|author=|date=23 February 2015|publisher=|access-date=25 April 2019|via=The Economic Times}}</ref><ref>{{cite web|url=https://www.business-standard.com/article/companies/ahmedabad-based-intas-pharma-launches-biosimilar-in-eu-115022300721_1.html|title=Ahmedabad-based Intas Pharma launches biosimilar in EU|first=B. S.|last=Reporter|date=23 February 2015|publisher=|access-date=25 April 2019|via=Business Standard}}</ref> In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for $764 million.<ref>{{Cite news|last=Dandekar|first=Vikas|last2=Barman|first2=Arijit|date=2016-10-06|title=Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-buys-tevas-uk-ireland-assets-for-764-million-to-break-into-global-top-20-generic-players-club/articleshow/54696609.cms?from=mdr|access-date=2020-05-08}}</ref><ref>{{cite web|title=Chudgars of Intas: A family that dreams big together|url=https://economictimes.indiatimes.com/news/company/corporate-trends/chudgars-of-intas-a-family-that-dreams-big-together/articleshow/54725284.cms|last1=Dandekar|first1=Vikas|last2=Barman|first2=Arijit|date=7 October 2016|publisher=|via=The Economic Times|access-date=25 April 2019}}</ref>
The company had an annual revenue of $1.8 [[Billion]] (₹12,600 [[crore]]) in 2019 and a profit of $204 [[1,000,000|Million]] (₹1,248 crore) after taxes in the financial year 2019. The company's 69% of revenue came from international operations in the FY2019 while just 31% came from [[India]].<ref>{{Cite web|title=Intas Pharmaceuticals - Crunchbase Company Profile & Funding|url=https://www.crunchbase.com/organization/intas-pharmaceuticals|access-date=2021-07-04|website=Crunchbase|language=en}}</ref><ref>{{Cite web|title=Financials – Intas Pharmaceuticals Ltd.|url=https://www.intaspharma.com/financials/|access-date=2021-07-04|language=en-US}}</ref>


== Acquisitions ==
⚫
In 2017, the company announced acquisition of Actavis UK Ltd. & Actavis Ireland Ltd from [[Teva Pharmaceuticals|Teva Pharmaceutical Industries Ltd]], for an enterprise value of GBP 603 million.<ref>{{Cite web|title=Intas Pharmaceuticals Completes Deal to Acquire Actavis|url=https://www.moneycontrol.com/news/business/companies/intas-pharmaceuticals-completes-deal-to-acquire-actavis-941493.html|website=Moneycontrol|access-date=2020-05-08}}</ref>

[[File:Intas product development timeline.png|thumb|Intas Biosimilar development timeline]]
[[File:Rituximab ( MabTas ).jpg|thumb|MabTas is Rituximab biosimilar of Intas]]
[[File:Accofil.JPG|thumb|Intas manufactured Filgrastim registered in EU]]


⚫
* In 2016, Intas acquired the assets of [[Teva Pharmaceuticals]] in the [[United Kingdom|UK]] and [[Ireland]] for [[Dollar sign|$]]764 million.<ref>{{Cite news|last=Dandekar|first=Vikas|last2=Barman|first2=Arijit|date=2016-10-06|title=Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/intas-buys-tevas-uk-ireland-assets-for-764-million-to-break-into-global-top-20-generic-players-club/articleshow/54696609.cms?from=mdr|access-date=2020-05-08}}</ref><ref>{{cite web|last1=Dandekar|first1=Vikas|last2=Barman|first2=Arijit|date=7 October 2016|title=Chudgars of Intas: A family that dreams big together|url=https://economictimes.indiatimes.com/news/company/corporate-trends/chudgars-of-intas-a-family-that-dreams-big-together/articleshow/54725284.cms|access-date=25 April 2019|publisher=|via=The Economic Times}}</ref>
⚫
* In 2017, the company announced acquisition of [[Actavis|Actavis UK Ltd.]] & [[Actavis|Actavis Ireland Ltd]] from [[Teva Pharmaceuticals|Teva Pharmaceutical Industries]], for an enterprise value of [[Pound sterling|£]]603 million.<ref>{{Cite web|title=Intas Pharmaceuticals Completes Deal to Acquire Actavis|url=https://www.moneycontrol.com/news/business/companies/intas-pharmaceuticals-completes-deal-to-acquire-actavis-941493.html|access-date=2020-05-08|website=Moneycontrol}}</ref><ref>{{Cite web|last=Bureau|first=Our|title=Intas to acquire UK &amp; Ireland generics businesses from Teva for £603 million|url=https://www.thehindubusinessline.com/companies/intas-to-acquire-uk-amp-ireland-generics-businesses-from-teva-for-603-million/article21712880.ece|access-date=2021-07-04|website=@businessline|language=en}}</ref>
== References ==
== References ==
{{Reflist}}
{{Reflist}}


== External links ==
== External Links ==
* [http://www.intaspharma.com/ Intas Pharmaceuticals Ltd.]
[https://www.intaspharma.com/ Official site]

{{Authority control}}

[[Category:Indian brands]]
[[Category:Indian brands]]
[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies of India]]

Revision as of 06:09, 20 August 2021

Intas Biopharmaceuticals Ltd is an Indian multinational company headquartered in Ahmedabad, Gujarat. It was founded by Dr. Urmish Chudgar and is now headed by Hasmukh Chudgar. The Biologics unit (BU) of the company is located in Ahmedabad and it is one of the leading biosimilar product manufacturers in Asia. The unit (BU) has its own biopharmaceutical operations with a R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.[1]

Intas Biopharmaceuticals
Company typePrivate
IndustryBiopharmaceuticals
Founded1984; 40 years ago (1984)
FounderDr. Urmish Chudgar
HeadquartersAhmedabad, Gujarat,
India
Area served
Worldwide
ProductsNeukine (GCSF)
Erykine (EPO)
Intalfa (IFN)
Pegasta (Peg GCSF)
Terifrac (Teriparatide)
Mabtas (Rituximab)
Folisurge (FSH)
RevenueIncrease ₹ 12,600 crore
(US$ 1.8 Billion) (2019)
Increase ₹ 1,248 crore
(US$ 204 Million) (2019)
Number of employees
8000+ (2021)
Websitewww.intaspharma.com

History

Intas Biopharmaceuticals Limited was set up in 1980 by Dr. Urmish Chudgar, a hematologist, as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Hasmukh Chudgar.

Present

The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.[2]

Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.[3][4]

Products

In 2015, the company launched Accofil, a treatment for immune system disorders.[5][6]

Products of Intas Biopharmaceuticals and timeline
  • MabTas is Rituximab biosimilar of Intas
    MabTas is Rituximab biosimilar of Intas
  • Intas manufactured Filgrastim (Accofil) registered in EU
    Intas manufactured Filgrastim (Accofil) registered in EU
  • Intas Biosimilar development timeline
    Intas Biosimilar development timeline

Financials

The company had an annual revenue of $1.8 Billion (₹12,600 crore) in 2019 and a profit of $204 Million (₹1,248 crore) after taxes in the financial year 2019. The company's 69% of revenue came from international operations in the FY2019 while just 31% came from India.[7][8]

Acquisitions

References

  1. ^ "Intas mfg unit gets EU-GMP certification". The Economic Times. 13 June 2007.
  2. ^ "Intas mfg unit gets EU-GMP certification". The Economic Times. Retrieved 4 July 2021.
  3. ^ "About Us – Intas Pharmaceuticals Ltd". Retrieved 4 July 2021.
  4. ^ "Intas's Growth Driver : Biopharmaceuticals". NCK Pharma. 23 January 2015. Retrieved 4 July 2021.
  5. ^ "Intas Pharma launches its first biosimilar product Accofil in Europe". 23 February 2015. Retrieved 25 April 2019 – via The Economic Times.
  6. ^ Reporter, B. S. (23 February 2015). "Ahmedabad-based Intas Pharma launches biosimilar in EU". Retrieved 25 April 2019 – via Business Standard.
  7. ^ "Intas Pharmaceuticals - Crunchbase Company Profile & Funding". Crunchbase. Retrieved 4 July 2021.
  8. ^ "Financials – Intas Pharmaceuticals Ltd". Retrieved 4 July 2021.
  9. ^ Dandekar, Vikas; Barman, Arijit (6 October 2016). "Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club". The Economic Times. Retrieved 8 May 2020.
  10. ^ Dandekar, Vikas; Barman, Arijit (7 October 2016). "Chudgars of Intas: A family that dreams big together". Retrieved 25 April 2019 – via The Economic Times.
  11. ^ "Intas Pharmaceuticals Completes Deal to Acquire Actavis". Moneycontrol. Retrieved 8 May 2020.
  12. ^ Bureau, Our. "Intas to acquire UK & Ireland generics businesses from Teva for £603 million". @businessline. Retrieved 4 July 2021. {{cite web}}: |last= has generic name (help)

Official site

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Intas_Biopharmaceuticals&oldid=1039697080"